GO:1905841 response to oxidopamine: Neurotoxicity Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905841 (response to oxidopamine) is a biological_process describing any change in a cell or organism caused by an oxidopamine stimulus.
• Oxidopamine (6-hydroxydopamine) is a neurotoxin widely used to model Parkinson disease by damaging dopaminergic neurons.
• The response includes oxidative stress sensing, reactive cysteine modification, autophagy, and altered gene expression.
• SH-SY5Y neuroblastoma cells are a standard in vitro model for studying oxidopamine-induced neurotoxicity.
• Rodent hemiparkinsonian models link oxidopamine responses to dyskinesia, nociception, and sensorimotor dysfunction.
• CRISPR knockout, knock-in, and overexpression models help dissect causal genes in the oxidopamine response.
Description
GO:1905841, response to oxidopamine, is a Gene Ontology biological_process term that captures any change in the state or activity of a cell or organism following exposure to oxidopamine. Oxidopamine, also known as 6-hydroxydopamine, is a catecholamine analog that selectively enters dopaminergic neurons and generates oxidative stress, making it a cornerstone tool for Parkinson disease research. The term therefore describes a complex cellular reaction that spans oxidative stress sensing, protein modification, autophagy, and transcriptional reprogramming. Understanding this response is critical because it connects a defined chemical stimulus to measurable molecular and behavioral outcomes in neurotoxicity models. Researchers use GO:1905841 to annotate genes and pathways that mediate neurotoxin sensitivity, dopaminergic degeneration, and compensatory plasticity. The term also provides a shared vocabulary for comparing in vitro cell models with in vivo rodent and zebrafish systems.
response to oxidopamine At A Glance
| GO ID | GO:1905841 |
|---|---|
| GO term | response to oxidopamine |
| Ontology | biological_process |
| Synonym | None listed |
| Definition | Any process that results in a change in state or activity of a cell or an organism as a result of an oxidopamine stimulus. |
| Major function | Mediates cellular and organismal responses to the neurotoxin oxidopamine, including oxidative stress, autophagy, and gene expression changes. |
| Related stimulus | Oxidopamine (6-hydroxydopamine), a dopaminergic neurotoxin. |
| Common models | SH-SY5Y cells, rodent hemiparkinsonian models, zebrafish larvae. |
| Disease relevance | Parkinson disease, levodopa-induced dyskinesia, parkinsonian nociceptive disorders. |
What Is GO:1905841?
In plain terms, GO:1905841 describes everything a cell or organism does after it encounters oxidopamine. The official definition states: any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an oxidopamine stimulus. This includes immediate biochemical reactions such as reactive cysteine oxidation, downstream signaling changes, autophagic responses, and longer-term behavioral or physiological adaptations observed in animal models. The term is a biological_process, not a molecular function or cellular component, and it has no synonyms in QuickGO.
Why Is response to oxidopamine Important in Cell Biology?
GO:1905841 is important because oxidopamine is one of the most widely used neurotoxins for modeling Parkinson disease, and the response to it defines how dopaminergic cells sense and survive oxidative injury. Annotating genes to this term helps researchers separate direct neurotoxic mechanisms from compensatory or secondary effects, which is essential for target discovery. The term also bridges in vitro and in vivo findings, since oxidopamine responses are measured in cell lines, rodents, and zebrafish. In translational research, understanding this response supports the development of neuroprotective strategies and the interpretation of dyskinesia and pain phenotypes in parkinsonian models.
• Provides a standardized annotation for genes and pathways activated by oxidopamine.
• Links oxidative stress chemistry to cellular outcomes such as autophagy and apoptosis.
• Supports Parkinson disease modeling in SH-SY5Y cells and rodent hemiparkinsonian models.
• Helps interpret levodopa-induced dyskinesia mechanisms in preclinical studies.
• Enables cross-species comparison using zebrafish and rodent behavioral assays.
• Guides CRISPR screens for modifiers of neurotoxin sensitivity.
• Connects molecular chaperone and autophagy pathways to dopaminergic neuron survival.
• Aids in understanding parkinsonian sensorimotor and nociceptive dysfunction.
• Facilitates biomarker discovery through chemoproteomic profiling of reactive cysteines.
• Informs neuroprotective drug development targeting oxidopamine-responsive pathways.
What Happens During response to oxidopamine?
Oxidopamine uptake and oxidative stress initiation
In simple terms: Oxidopamine enters cells and starts producing harmful reactive molecules.
Oxidopamine is taken up by dopaminergic neurons and undergoes autoxidation, generating reactive oxygen species and quinones that damage cellular components. This initial oxidative burst is the trigger for the entire GO:1905841 response and is commonly measured in SH-SY5Y neuroblastoma cells as an in vitro neurotoxicity model. Chemoproteomic studies have shown that this phase involves widespread modification of reactive cysteines in proteins, providing a molecular snapshot of early oxidative stress.
Reactive cysteine modification and redox signaling
In simple terms: Oxidopamine changes specific cysteine switches on proteins, altering their activity.
A key event in the response to oxidopamine is the oxidation of reactive cysteine residues, which can change protein function and trigger redox signaling. Chemoproteomic profiling of reactive cysteines in response to oxidative stress induced by 6-hydroxydopamine has identified target proteins and pathways that mediate cellular adaptation or injury. These modifications represent a direct molecular readout of the oxidopamine stimulus and are central to the biological_process defined by GO:1905841.
Autophagy and protein quality control
In simple terms: Cells try to clean up damaged components by activating autophagy.
Autophagy is involved in the response to oxidopamine and in levodopa-induced dyskinesia, a motor complication in Parkinson disease models. Studies in hemiparkinsonian rodents indicate that autophagic pathways are engaged during the response to dopaminergic injury and may influence dyskinesia severity. This places autophagy within the GO:1905841 framework as a downstream adaptive mechanism that can be experimentally modulated.
Gene expression and neurotrophic signaling changes
In simple terms: The cell switches many genes on or off to cope with the toxin.
Exposure to oxidopamine alters gene expression programs, including those related to neurotrophic signaling and stress responses. In SH-SY5Y cells, all-trans-retinoic acid differentiation changes the cellular response to neurotoxic insults, illustrating how gene expression states modify GO:1905841 outcomes. These transcriptional changes are often measured by RNA-seq or qPCR in neurotoxicity studies.
Behavioral and sensorimotor consequences in vivo
In simple terms: In animals, the response shows up as movement and pain changes.
In hemiparkinsonian rats, oxidopamine-induced dopaminergic lesions produce nociceptive and sensorimotor dysfunctions that are modulated by brainstem and spinal circuits. The vasomotor response to dopamine is altered in the rat model of levodopa-induced dyskinesia, linking the oxidopamine response to vascular and motor phenotypes. Zebrafish larvae can also be used to screen for phenotypic and mutant responses to neurotoxic stimuli using on-demand electric stimulation.
Key Genes Involved in GO:1905841 response to oxidopamine
The following genes and proteins are experimentally linked to the response to oxidopamine and related neurotoxicity models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TH | Tyrosine hydroxylase, rate-limiting enzyme in dopamine synthesis | Marker of dopaminergic neurons in oxidopamine lesion models |
| SLC6A3 | Dopamine transporter, mediates oxidopamine uptake | Determines selective toxicity to dopaminergic neurons |
| MAP1LC3B | Autophagy marker, involved in autophagosome formation | Linked to autophagy in levodopa-induced dyskinesia |
| SQSTM1 | Autophagy receptor, clears damaged proteins | Readout of autophagic flux after oxidopamine |
| NGF | Neurotrophic factor supporting neuron survival | Modifies response to neurotoxic insult in SH-SY5Y cells |
| BDNF | Neurotrophic factor involved in plasticity | Associated with dyskinesia and sensorimotor changes |
| DRD1 | Dopamine receptor D1 | Mediates motor and nociceptive responses in hemiparkinsonian rats |
| DRD2 | Dopamine receptor D2 | Contributes to vasomotor and dyskinetic responses |
| GAD1 | Glutamate decarboxylase, GABA synthesis | Brainstem modulation of parkinsonian sensorimotor dysfunction |
| GAD2 | Glutamate decarboxylase 2, GABA synthesis | Involved in basal ganglia circuit changes |
| SLC6A4 | Serotonin transporter | Modulates dopamine release and dyskinesia |
| COMT | Catechol-O-methyltransferase, dopamine catabolism | Affects levodopa response and dyskinesia |
| MAOB | Monoamine oxidase B, dopamine catabolism | Influences oxidative stress and dopamine turnover |
| NEFL | Neurofilament light chain | Marker of neuronal damage in parkinsonian models |
| NEFM | Neurofilament medium chain | Structural marker in brainstem and spinal circuits |
| GFAP | Astrocyte marker | Glial response to oxidopamine lesion |
| AIF1 | Microglial marker | Neuroinflammation in response to oxidopamine |
How Is response to oxidopamine Regulated?
The response to oxidopamine is regulated at multiple levels, including redox-sensitive cysteine switches, autophagic flux, and neurotrophic signaling. Autophagy-related pathways are involved in levodopa-induced dyskinesia, suggesting that mTOR-dependent or independent autophagic regulation can shape the response to dopaminergic injury. Dopamine receptor and transporter activity also modulate the intensity and selectivity of the oxidopamine response in vivo.
response to oxidopamine and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TH | Parkinson disease, dopaminergic degeneration | SH-SY5Y knockout and oxidopamine treatment |
| MAP1LC3B | Levodopa-induced dyskinesia, autophagy | Hemiparkinsonian rat with autophagy modulation |
| DRD1 | Parkinsonian nociception and dyskinesia | Rodent hemiparkinsonian model |
| SLC6A3 | Dopaminergic neurotoxicity | Zebrafish or SH-SY5Y uptake assays |
| GFAP | Neuroinflammation in Parkinson disease | Oxidopamine-lesioned rodent brain |
Parkinson disease and dopaminergic degeneration
Oxidopamine is used to lesion dopaminergic neurons in animal models of Parkinson disease, and GO:1905841 captures the cellular response to this injury. The response includes oxidative stress, autophagy, and gene expression changes that contribute to neurodegeneration. Hemiparkinsonian rats develop nociceptive and sensorimotor dysfunctions that model non-motor symptoms of Parkinson disease.
Levodopa-induced dyskinesia
Autophagy is involved in levodopa-induced dyskinesia, a major complication of Parkinson disease therapy. The vasomotor response to dopamine is altered in the rat model of levodopa-induced dyskinesia, linking oxidopamine-induced lesions to vascular and motor phenotypes. These findings connect GO:1905841 to treatment-related motor complications.
Parkinsonian pain and sensorimotor disorders
Brainstem and spinal cord circuits modulate parkinsonism-induced orofacial sensorimotor dysfunctions and nociceptive disorders. Nociceptive responses to levodopa-induced dyskinesia have been characterized in hemiparkinsonian rats, providing behavioral readouts for the oxidopamine response. These studies show that GO:1905841 has organism-level consequences beyond the nigrostriatal system.
From response to oxidopamine-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene mediate oxidopamine toxicity? | CRISPR knockout in SH-SY5Y cells followed by oxidopamine treatment |
| Does a point mutation alter oxidative stress sensing? | Point-mutation knock-in in neuroblastoma cells |
| Does a risk variant change autophagy flux? | Knock-in of the variant with LC3B reporter |
| Where is a protein localized after oxidopamine? | Tagged knock-in with fluorescent tag |
| Does overexpression protect dopaminergic neurons? | Overexpression in SH-SY5Y or primary neurons |
| Does a gene modify behavioral dyskinesia? | Hemiparkinsonian rodent with gene manipulation |
How to Study the response to oxidopamine Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cell viability assay | Cell survival after oxidopamine | SH-SY5Y neurotoxicity screening |
| ROS detection | Oxidative stress levels | Early response to oxidopamine |
| Chemoproteomics | Reactive cysteine modification | Target discovery in oxidative stress |
| LC3B flux assay | Autophagic activity | Autophagy involvement in dyskinesia |
| Behavioral testing | Nociceptive and motor responses | Hemiparkinsonian rat models |
| Vasomotor response assay | Vascular response to dopamine | Levodopa-induced dyskinesia model |
| Zebrafish electric stimulation | Phenotypic response to stimuli | Mutant and chemical screening |
| RNA-seq | Gene expression changes | Transcriptional response to oxidopamine |
Cell viability and oxidative stress assays
Oxidopamine toxicity is commonly measured in SH-SY5Y cells using viability assays, reactive oxygen species detection, and caspase activity. These assays provide the first readout of GO:1905841 activation and are used to compare wild-type and CRISPR-edited cells.
Chemoproteomics of reactive cysteines
Chemoproteomic profiling identifies cysteine residues modified by oxidative stress induced by 6-hydroxydopamine. This method reveals direct molecular targets of the oxidopamine response and can be combined with CRISPR knockout to validate specific proteins.
Autophagy and protein degradation assays
Autophagic flux is assessed by LC3B lipidation, SQSTM1 degradation, and microscopy in cells and rodent models. These methods link GO:1905841 to protein quality control and dyskinesia mechanisms.
Behavioral and electrophysiological phenotyping
Hemiparkinsonian rodents are evaluated for nociceptive responses, orofacial sensorimotor function, and vasomotor responses to dopamine. Zebrafish larvae can be screened for phenotypic responses using on-demand electric stimulation.
How CRISPR Can Be Used to Study GO:1905841 response to oxidopamine
Knockout
CRISPR knockout of candidate genes in SH-SY5Y or primary neurons followed by oxidopamine treatment tests whether the gene is required for the response. Knockout of autophagy genes can reveal their role in dyskinesia-related pathways.
Point Mutation
Point-mutation knock-in can model specific cysteine-to-serine changes identified by chemoproteomics, testing whether a single redox-sensitive residue mediates the oxidopamine response. This approach links molecular modifications to functional outcomes.
Knock-in
Knock-in of disease-associated variants or reporter tags allows tracking of protein localization and function after oxidopamine exposure. Tagged knock-in models are useful for imaging and biochemical studies.
Overexpression
Overexpression of neurotrophic factors or antioxidant proteins in SH-SY5Y cells can test protection against oxidopamine toxicity. Overexpression in rodent models can assess effects on dyskinesia and sensorimotor behavior.
How EDITGENE Supports response to oxidopamine Research
Researchers studying response to oxidopamine-related genes often need to determine whether a candidate gene is causally involved in neurotoxin sensitivity, oxidative stress adaptation, or behavioral outcomes. EDITGENE provides CRISPR-based cell and animal model services to test these hypotheses with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for response to oxidopamine research.
Frequently Asked Questions About response to oxidopamine
What is GO:1905841?
GO:1905841 is the Gene Ontology biological_process term for response to oxidopamine, describing any change in a cell or organism caused by an oxidopamine stimulus.
What is oxidopamine?
Oxidopamine, also called 6-hydroxydopamine, is a neurotoxin used to model Parkinson disease by damaging dopaminergic neurons.
What genes are involved in response to oxidopamine?
Genes such as TH, SLC6A3, MAP1LC3B, SQSTM1, DRD1, DRD2, and GFAP are experimentally linked to the response.
How is response to oxidopamine studied in cells?
SH-SY5Y neuroblastoma cells are treated with oxidopamine and assayed for viability, oxidative stress, autophagy, and gene expression.
What animal models are used for oxidopamine research?
Hemiparkinsonian rodents and zebrafish larvae are used to study behavioral, sensorimotor, and nociceptive responses.
Is autophagy involved in the oxidopamine response?
Yes, autophagy is involved in levodopa-induced dyskinesia and is part of the cellular response to dopaminergic injury.
What is the role of reactive cysteines in oxidopamine response?
Oxidopamine induces oxidative stress that modifies reactive cysteines, altering protein function and signaling.
Can CRISPR be used to study response to oxidopamine?
Yes, CRISPR knockout, knock-in, and overexpression models can test causal roles of genes in the oxidopamine response.
What diseases are linked to GO:1905841?
Parkinson disease, levodopa-induced dyskinesia, and parkinsonian nociceptive disorders are linked to the oxidopamine response.
How does EDITGENE support response to oxidopamine research?
EDITGENE provides CRISPR cell models, library screening, and bioinformatics to study genes in GO:1905841.
Conclusion
GO:1905841 response to oxidopamine provides a precise ontology framework for studying how cells and organisms react to a classic Parkinson disease neurotoxin. The response spans oxidative cysteine modification, autophagy, gene expression, and behavioral outcomes, with strong experimental support from cell, rodent, and zebrafish models. Researchers can leverage CRISPR knockout, knock-in, and overexpression models to dissect causal genes and identify neuroprotective targets within this process.
References
- 1. Cheung YT et al.. 2009. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research.. Neurotoxicology 30(1):127-35 PMID: 19056420
- 2. Murtada R et al.. 2025. Chemoproteomic Profiling of Reactive Cysteines in Response to Oxidative Stress Induced by 6-Hydroxydopamine.. Proteomics 25(20):47-55 PMID: 40999799
- 3. Nascimento GC et al.. 2018. Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.. Neurotox Res 34(4):799-807 PMID: 29611150
- 4. Feyder M et al.. 2021. Involvement of Autophagy in Levodopa-Induced Dyskinesia.. Mov Disord 36(5):1137-1146 PMID: 33460487
- 5. Booth S et al.. 2021. The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.. Mov Disord 36(4):938-947 PMID: 33135810
- 6. Khalili A et al.. 2019. Phenotypic chemical and mutant screening of zebrafish larvae using an on-demand response to electric stimulation.. Integr Biol (Camb) 11(10):373-383 PMID: 31851358
- 7. Nascimento GC et al.. 2023. Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.. Int J Mol Sci 24(15) PMID: 37569642
- 8. Charles KA et al.. 2025. Interplay between subthalamic nucleus and spinal cord controls parkinsonian nociceptive disorders.. Brain 148(1):313-330 PMID: 38916480
